There's a lot of confusion around what the FDA's "Emergency Use Authorization" for HCQ actually did and what rescinding it means. The EUA was never meant to expand the use of HCQ and it only applied to the supply donated to the National Strategic Stockpile (NSS). (thread) 
In fact, the EUA was put in place to improperly restrict use of the donated drugs to only hospitalized patients. The now infamous "whistle-blower" Rick Bright, PhD, admits that he pushed for the EUA to impede use (not expand it).
The Trump Administration wanted to make the donated HCQ available for early treatment outside of hospital settings, but Rick Bright pushed for an EUA to restrict use to hospitals where it is often too late for the treatment to be beneficial.
Today's revocation of the EUA by the FDA is, in a sense, an admission that the agency erred by limiting the supply in the NSS to use in hospitalized patients.
A good outcome of today's FDA order is that it states that the NSS supply of HCQ "can be distributed in interstate commerce." This means it could be available for off-label early treatment, instead of limited to only hospitalized patients.
So rescinding the EUA does NOT meant that HCQ cannot be used for early treatment of COVID-19 patients. It means that the supply of the drug stuck in the stockpile is now free from the EUA's retractions, once it is released into the consumer supply chain.
"Retractions" should be "restrictions" in tweet above.
Articles and research supporting prophylaxis and early treatment with HCQ include: docs.google.com/document/d/1vD…
Interestingly the FDA seems to admit is was initially factoring in the now discredited Lancet article in the analysis that led to today's order, before it was withdrawn.
